Drug Insight: Advances in renal cell carcinoma and the role of targeted therapies

Nature Clinical Practice Oncology

Volumn 4, Issue 8, 2007, Pages 470-479

  Larkin, James M G ^a   Chowdhury, Simon ^b   Gore, Martin E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; INTERLEUKIN 2; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADJUVANT THERAPY; ANEMIA; ANOREXIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLEAR CELL CARCINOMA; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; GENE TARGETING; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; OLIGURIA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEINURIA; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN EXFOLIATION; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; VASCULAR DISEASE; WEIGHT REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 34548562158     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0901     Document Type: Review

References (81)

1. Landis SH et al. Cancer statistics, 1999. CA Cancer J Clin 49: 8-31
2. Motzer RJ et al. (2004) Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 10: 6302S-6303S
3. Motzer RJ et al. (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20: 2376-2381
4. Cheville JC et al. (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612-624
5. Beck SD et al. (2004) Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11: 71-77
6. Yao M et al. (2002) VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94: 1569-1575
7. Kim WY and Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004
8. Ohh M et al. (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427
9. Ferrara N et al. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400
10. Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434
11. Yagoda A and Bander NH (1989) Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 44: 338-345
12. Harris DT (1983) Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 10: 422-430
13. Horoszewicz JS and Murphy GP (1989) An assessment of the current use of human interferons in therapy of urological cancers. J Urol 142 1173-1180
14. [No authors listed] (1999) Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353: 14-17
15. Pyrhonen S et al. (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859-2867
16. Fossa S et al. (1995) Interferon-alpha and survival in renal cell cancer. Br J Urol 76: 286-290
17. Rosenberg SA et al. (1998) Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228 307-319
18. Negrier S et al. (2005) Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial [abstract #4511]. J Clin Oncol 23 (Suppl 16S)
19. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211-225
20. Gunningham SP et al. (2001) Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: Regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 61: 3206-3211
21. Sulzbacher I et al. (2003) Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120: 107-112
22. Uhlman DL et al. (1995) Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: Correlation with metastatic behavior and prognosis. Clin Cancer Res 1: 913-920
23. Druker BJ et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037
24. van Oosterom AT et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358: 1421-1423
25. Giaccone G et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22: 777-784
26. Herbst RS et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 22: 785-794
27. Kris MG et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290: 2149-2158
28. Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132
29. Lynch TJ et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
30. Paez JG et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500
31. Pao W et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 13306-13311
32. Heinrich MC et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349
33. Debiec-Rychter M et al. (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093-1103
34. Corless CL et al. (2005) PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23: 5357-5364
35. Prenen H et al. (2006) Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12: 2622-2627
36. Antonescu CR et al. (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182-4190
37. Wardelmann E et al. (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12: 1743-1749
38. Rugo HS et al. (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 23: 5474-5483
39. Rini B et al. (2005) AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) [abstract #4509]. J Clin Oncol 23 (Suppl 16S)
40. Wilhelm SM et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109
41. Sridhar SS et al. (2005) Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4: 677-685
42. Strumberg D et al. (2005) Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965-972
43. Strumberg D et al. (2002) Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 40: 580-581
44. Moore M et al. (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16: 1688-1694
45. Awada A et al. (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced refractory solid tumours. Br J Cancer 92: 1855-1861
46. Ratain MJ et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505-2512
47. Escudier B et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134
48. Therasse P et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
49. Eisen T et al. (2006) Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival [abstract #4524]. J Clin Oncol 24 (Suppl 18S)
50. Escudier B et al. (2006) Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC) [abstract #4501]. J Clin Oncol 24 (Suppl 18S)
51. Mendel DB et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 327-337
52. O'Farrell AM et al. (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605
53. Fiedler W et al. (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105: 986-993
54. O'Farrell AM et al. (2003) An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9: 5465-5476
55. Faivre S et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35
56. Matzer RJ et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24
57. Motzer RJ et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524
58. Rini BI et al. (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99: 81-83
59. Motzer RJ et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124
60. Hudson CC et al. (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014
61. Shin Lee J et al. (2003) Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol 84: 166-172
62. Hara S et al. (2005) Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16: 928-933
63. Vignot S et al. (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537
64. Raymond E et al. (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22: 2336-2347
65. Atkins MB et al. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909-918
66. Hudes G et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281
67. Amato RJ et al. (2006) A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) [abstract #4530]. J Clin Oncol 24 (Suppl 18S)
68. Atkins M et al. (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11: 3714-3721
69. Hainsworth JD et al. (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23: 7889-7896
70. Bukowski RM et al. (2006) Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC) [abstract #4523]. J Clin Oncol 24 (Suppl 18S)
71. Azad NS et al. (2006) Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab [abstract #3004]. J Clin Oncol 24 Suppl 18S)
72. Sosman JA et al. (2006) A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts) [abstract #3031]. J Clin Oncol 24 (Suppl 18S)
73. Gollob J et al. (2006) Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC) [abstract #4538]. J Clin Oncol 24 (Suppl 18S)
74. Ryan CW et al. (2006) Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412 [abstract #4525]. J Clin Oncol 24 (Suppl 18S)
75. Temaskar I et al. (2006) Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents [abstract #4597]. J Clin Oncol 24 (Suppl 18S)
76. Rini BI et al. (2006) Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC) [abstract #4522]. J Clin Oncol 24 (Suppl 18S)
77. Clark JI et al. (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial. J Clin Oncol 21: 3133-3140
78. Messing EM et al. (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21 1214-1222
79. Pizzocaro G et al. (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study. J Clin Oncol 19: 425-431
80. Atzpodien J et al. (2005) Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92: 843-846
81. Zalcberg JR et al. (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer 41: 1751-1757